Navigation Links
Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Date:3/13/2008

BERKELEY, Calif., March 13 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced its fourth quarter and full year financial results for 2007. Participants may access the archived webcast of the conference call from the investor relations section of Nile's website at http://www.nilethera.com. The webcast will remain available on the company's website until the next quarterly conference call.

For the fourth quarter of 2007, Nile reported a net operating loss of $2.7 million, or $0.11 per share. For the full year, net operating loss was $9.5 million, or $0.56 per share. Weighted average shares outstanding for the fourth quarter and for all of 2007 were 24.1 million and 16.9 million, respectively.

Nile reported no revenue during the fourth quarter and grant income of $0.1 million during 2007. For the fourth quarter and for all of 2007, Nile reported net interest income of $0.2 million and net interest expense of $0.8 million, respectively.

As of December 31, 2007, Nile had cash and cash equivalents of $16.2 million compared to $18.0 million at September 30, 2007. Cash and cash equivalents declined $1.8 million in the fourth quarter of 2007 from the third quarter of 2007 as cash was used for operations.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in clinical studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
2. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
6. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
7. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
8. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... -- Insero Health, Inc., a company developing natural compounds to ... disorders, is today reporting top-line results from a Phase ... with drug-resistant epilepsy.  The data are being presented at ... by Dr. Steven Schachter , Harvard ... Board.  In this study, INS001 appeared safe and well ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 RURO ... ezColony version 4.1, a versatile refinement to the ... software solution, improves its advanced methodical management for ... with ezColony 4.1. The network-based platform provides user ... effective research. While continuing to emphasize streamlined tasks, ...
(Date:5/17/2013)... 2013 Tooth decay is an epidemic in ... of the disease. The World Health Organization says that worldwide, ... adults have cavities. What are the long-term effects of this ... strong connection between the oral bacterial imbalance and serious systemic ... rampant, yet it is also 100% preventable? Answer: there has ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... ... $20 million in yearly revenues and have experienced significant growth over the last 12 months. ... ... Orange County has become a hub for innovation and growth and Southern California Venture Network ...
... , Hopkinton, Mass., Sept. 24 Caliper Life ... tools and services for drug discovery and life sciences research, today ... World Molecular Imaging Congress (WMIC) in Montreal, Canada. Rediject D-Luciferin Ultra ... Caliper,s IVIS optical imaging systems. , , ...
... , , SALT LAKE CITY, ... care through the development of molecular diagnostics, announced today that ... to spine specialists in the United States. SCOLISCORE is a ... of scoliosis, an abnormal lateral curvature of the spine. Spine ...
Cached Biology Technology:Southern California Venture Network to Recognize Local Companies At 2009 Emerging Growth Awards 2Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 2Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 3Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test 2Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test 3
(Date:5/18/2013)... (May 18, 2013) Research presented today at Digestive ... research, with findings about the impact of coffee on ... , While coffee consumption recently has been associated with ... even a few more cups of java each month ... liver disease. Researchers at the Mayo Clinic, Rochester, MN, ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) ... diet and lifestyle. , Individuals suffering from ... strength, fatigue and poor quality of life. These ... remission. A randomized, double blind, placebo-controlled study found ... corresponded to significant relief of these symptoms. ...
(Date:5/18/2013)... 2013) An increasing number of U.S. children ... resolve, according to research presented at Digestive Disease ... obesity, researchers at the Cleveland Clinic Children,s Hospital ... of exhaled breath compared to their lean counterparts. ... levels that can be correlated to potential complications ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3
... threat to the healthy growth of coral reefs in ... could one day treat human diseases, a new study ... UC San Diego has revealed. An analysis led ... laboratory at Scripps, has shown that the seaweed, a ...
... , Athens, Ga. Human breast milk is the best ... found what may be a new second bestformula made from ... professor of food science and technology in the College of ... hazelnut oil that better mimics the structure of mother,s milk, ...
... is available in German . In the ... sometimes, it is the most beautiful. A well-known example is the ... fan. A research team at Bielefeld University headed by the evolutionary ... mechanism is involved in mate choice among locusts. The male Siberian ...
Cached Biology News:Nuisance seaweed found to produce compounds with biomedical potential 2Hazelnuts improve infant formula 2A mating dance with Popeye arms 2
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Prostaglandin-E2 receptor EP2/EP3 Market Segment: GPCRs...
Biology Products: